<DOC>
	<DOCNO>NCT01491958</DOCNO>
	<brief_summary>Phase II trial evaluate safety &amp; efficacy Atorvastatin prophylaxis Acute Graft Versus Host Disease ( GVHD ) patient hematological malignance undergo human leukocyte antigen ( HLA ) -Matched Related Donor Hematopoietic Stem Cell Transplant ( HSCT ) .</brief_summary>
	<brief_title>Safety &amp; Efficacy Atorvastatin Prophylaxis Acute Graft Versus Host Disease Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>The study single-arm phase II single institutional trial evaluate safety efficacy atorvastatin prophylaxis acute GVHD patient hematological malignancy undergo HLA match related donor HSCT . This study explore two-pronged acute GVHD prophylaxis strategy , consist pre-treating consenting related donor atorvastatin stem cell mobilization collection , follow atorvastatin plus methotrexate/tacrolimus-based GVHD prophylaxis transplant recipient patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Donor Eligibility Criteria The donor must least 18 year age , willing/able provide inform consent . Complete medication list review potential negative interaction atorvastatin . The donor must HLAmatched sibling relative . Syngeneic donor eligible . Female donor childbearing potential negative pregnancy test , must breast feeding . Bilirubin , AST ALT must &lt; 2 x normal ; absence hepatic fibrosis/cirrhosis . Adequate renal function define serum creatinine clearance ≥ 40 % normal calculate CockcroftGault equation . Adequate cardiac function history congestive heart failure , uncontrolled atrial fibrillation ventricular tachyarrhythmias . Patient Eligibility Criteria Have hematologic malignancy require allogeneic HSCT , adequate organ function , serologic ( high resolution ) 6/6 class I human leukocyte antigen ( HLA ) A B molecular class II DRB1 match related donor , able give inform consent . Patients &gt; 18 ≤ 65 year comorbidity score ≤ 3 eligible myeloablative conditioning ( MAC ) , patient &gt; 65 year age , previous history autologous transplantation , high comorbidity index ( &gt; 3 ) eligible reduce intensity conditioning ( RIC ) transplantation . All patient must least one 6/6 HLAmatched sibling donor . Patient must provide informed consent Patients must leave ventricular ejection fraction &gt; 30 % , uncontrolled arrhythmias New York Heart Association class IIIIV heart failure . Bilirubin must &lt; 2 x normal ; absence hepatic fibrosis/cirrhosis . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) must &lt; 2 x normal ; absence hepatic fibrosis/cirrhosis . Serum creatinine clearance ≥40 % normal calculate CockcroftGault equation . Forced expiratory volume one second ( FEV1 ) diffusion capacity ; correct hemoglobin ( DLCO ) ≥ 50 % 40 % predict respectively . Karnofsky performance status &gt; 70 . A negative pregnancy test require woman child bear potential . Breast feeding permit . No HIV infection . Patients immune dysfunction significantly high risk toxicity intensive immunosuppressive therapy . No evidence active bacterial , viral fungal infection time transplant conditioning . No active alcohol substance abuse within 6 month study entry . Prior allogeneic transplant acceptable . No history intolerance allergic reaction atorvastatin statin . Patients previously take atorvastatin statin eligible long contraindication switch atorvastatin 40mg/day opinion treat physician . Patients undergo Tcell deplete allogeneic transplantation eligible . Patients receive another investigational drug eligible unless clear Principal Investigator . Patients prior malignancy except resect basal cell carcinoma , treat carcinoma insitu , hematologic disease allogeneic HSCT treatment strategy , eligible . Cancer treat curative intent &lt; 5 year previously allow unless approve Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
</DOC>